bifidobacteria (B. longum 5336, from Morinaga Milk Industry Ltd) cultivated and analyzed as 1 recently described (8). Briefly, we observed strong, moderate and weak inducers of IL-10 for 2 propionibacteria at a bacteria:host cell ratio of 10:1 (MOI of 10, data not shown). We then 3 selected 5 strains to verify the dose dependency of the IL-10 induction (MOI of 5, 10 and 50), 4 confirming that the MOI of 10 dose was the most appropriate for screening purpose (Fig. 1A  5 and 1E). Pf ITGP20 and SI48 were found to be the most anti-inflammatory strains, while Pj 6 BIA455 and Pf BIA118 were less anti-inflammatory, although still more than the Pf BIA1 7 type strain (Fig. 1A) . Interestingly, for all the Pf strains tested, release of pro-inflammatory 8 mediators was very low: weak for TNFα (Fig. 1B) and almost undetectable for IL-12 and 9
IFNγ ( Fig. 1C and 1D ). The latter cytokine levels were even well below the levels described 10 for strains that offer little or no protection in in vivo inflammation models (9), see cutoff 11 levels in Fig. 1B-1D , while IL-10 levels were clearly at or above the cut-off level that 12 generally allows protection in a TNBS induced colitis model (9), Fig. 1A . This interesting 13 absence of pro-inflammatory cytokines was confirmed at the transcriptional level for a high, 14 intermediary and lower anti-inflammatory strain. Quantitative RT-PCR was performed on 15 RNA from PBMCs, isolated 4.5 h after induction (supplemental Fig. S1A , S1B, S1C) and 16 matched with ELISA quantifications of proteins of the corresponding donors in 24h 17 supernatants (Fig. S1D , S1E, S1F). This investigation confirmed the large diversity in the 18 immunomodulatory profiles amongst propionibacteria, quantified directly by the IL-10 19 cytokine, rather than the traditional IL-10/IL-12 ratio, which obviously, is inappropriate here. 
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Manuscript to be submitted to AEM as a short-form paper; version 06/10/2010 4 was used as described previously (female Balb/c mice, from Charles River, France, aged 7 1 weeks, n=10 per group). Pf SI48 significantly lowered the colitis-associated weight loss at 2 day 2 (10.5 % versus 16 %, p < 0.05, Fig. 2A ), confirmed by significant changes of the 3 macroscopic ( Fig. 2B and 2C , corresponding to 45 % of protection, p < 0.05), and histological 4 scores ( Fig. 2C and 2F) . Consistently, inflammatory markers such as colon length and colonic 5 myeloperoxidase (MPO) activity were also significantly reduced in the Pf group ( Fig. 2D and  6 2E, respectively). 7
In addition, we determined whether preventive treatment with P. freudenreichii ssp 8 could attenuate the severity of colonic injury and inflammation of mice infected with 9
Citrobacter rodentium. We used a non-lethal model of resistant Balb/c mice sustaining a 10 discrete and moderate colitis, but with quantifiable parameters (12, 32). Groups of 8 mice 11 received either a 5-days prophylactic oral treatment with Pf BIA118 or Pf SI48 (5×10 8 CFU 12
per day and per mouse) or the corresponding vehicle before a single oral inoculum (1x10 9 13 CFU) of C. rodentium strain DBS120 was administered (29). The counts of the fecal 14 pathogens increased progressively in infected-control mice (Fig. 3A) together with a slight 15 but significant decrease in whole body weight (Fig. 3B ) at 10-days post infection. The colitis-16 associated markers were also characterized by splenomegaly (assessed by spleen weight) and 17 increased blood Serum Amyloid A levels ( Fig. 3C and 3D ). Colons exhibited increased MPO 18 activity (see above) and crypt hyperplasia (assessed by crypts length measurements on 19 histological colon sections ( Fig. 3E and 3F , respectively). Although both Pf strains reduced 20 fecal pathogen counts only until day 5, strain Pf BIA118 significantly, and strain Pf SI48 to a 21 lesser extent, lowered most of the parameters measured at the end of the experiment (Fig. 3) . 22
It could be argued that such lowering rather evokes a delay of the onset of colitis than a direct 23 anti-inflammatory effect. However, based on previous kinetic studies at day 6 and 12 post 24 infection (PI) (Breton J. et al, unpublished data), we know that (i) the markers investigated are 25 highly correlated with fecal (and caecal) pathogen counts and time; (ii) Moreover, blood SAA 1 is an early marker that reaches a maximum at day 6 PI before it decreases at day 12 PI. 2
Consequently, beside an anti-infectious effect, such a delay would not reduced SAA levels in 3 probiotic-treated animals. Preventive effects of probiotics against C rodentium were already 4 described for lactobacilli and yeasts (14, 34) but, to our knowledge, never for dairy 5
propionibacteria. Alvarez et al. reported that feeding a Propionibacterium acidipropionici 6 supplement to mice prior to Salmonella typhimurium administration afforded a partial 7 protection against colonization by the pathogen, measured by a decrease in tissue colonization 8 by S. typhimurium and an increase in the mice survival rate (1). Here, Pf strains did not affect 9 colonization of C. rodentium on the longer term, but mainly alleviated inflammatory 10 symptoms linked to the infection. 11
12
A key role for surface compounds? 13
We suspected some surface compounds to be involved in the observed immunomodulatory 14 effects of dairy propionibacteria. Therefore, in a preliminary attempt to estimate the 15 importance of surface proteins, we removed the surface layer protein(s) by guanidium 16 chloride treatment as described previously (20) and as depicted by scanning electron 17 microscopy ( Fig. 1F ). This treatment indeed decreased the in vitro cytokine induction, turning 18 the strains to display a more pro-inflammatory profile on human PBMCs (Fig. 1G) . Although 19 the importance of surface layer proteins was already observed for a probiotic Lactobacillus 20 strain (17) this result needs to be extensively confirmed in vivo for different propionibacteria 21
ssp. Similarly, we can hypothesize that other components such as exopolysaccharides (EPS) 22 may also play an important role in the bacteria-host interaction as reported for other probiotic 23 genera, using both in vitro and in vivo models (4, 28, 30) . Presence of EPS is strain-dependent 24
in Pf (5) and preliminary data based on stimulation of PBMCs indicate a role of Pf EPS in 25 such interaction (data not shown). Finally, as established for bifidobacteria (11), specific cell-1 wall-associated proteins, which are known to be highly strain-dependent in Pf ssp, may also 2 contribute to a certain extent to the distinct immunomodulatory behavior of these bacteria. 3
The now available genome sequence of P. freudenreichii ssp shermanii CIRM-BIA1 (strain 4 included in this study) (7) will offer molecular approaches to further address this question. 5
Conclusions: 6
In the past, selection of probiotic strains was mainly empiric and based on technological 7 criteria. As probiotic intervention has strain-specific immunomodulatory effects, it is essential 8 to reliably select the most promising candidates for desired health applications. We described 9 before that the differential activation of human PBMCs by bacterial strains can be considered 10 as a predictive tool to identify gram positive probiotic strains with a potential anti-11 inflammatory effect in vivo (9). Here we compared the immune-based biodiversity of a set of 12 first 10, then 5 dairy propionibacteria together with established probiotic reference strains and 13 found an overall characteristic pattern with high levels of IL-10 and very low induction of IL-14 12, TNFα and IFNγ. In agreement with these profiles we obtained significant in vivo 15 protection against colitis in mice, suggesting that selected strains of dairy propionibacteria 16 and/or fermented dairy products containing these bacteria can possibly play a role in a diet 17 designed to prevent and/or limit the severity of IBD in humans. Moreover, experiments with 18 C. rodentium infection in mice, proved similar efficacy in the context of infectious disease. 
